Breaking news on Clinical trials
Brain MRIs May Provide An Early Diagnostic Marker For Dyslexia published
Tue, 24 Jan 2012 02:00:00 PST
Children at risk for dyslexia show differences in brain activity on MRI scans even before they begin learning to read, finds a study at Children's Hospital Boston. Since developmental dyslexia responds to early intervention, diagnosing children at risk before or during kindergarten could head off difficulties and frustration in school, the researchers say...
Human Hookworm Vaccine Trial published
Fri, 20 Jan 2012 08:00:00 PST
The Na-GST-1 antigen, a candidate for the first human hookworm vaccine developed by the Sabin Vaccine Institute (Sabin), has entered a Phase 1 human trial in Brazil, according to Sabin. For the vaccine product development partnership (PDP) headquartered at Sabin, the clinical trial is a considerable achievement. Worldwide, almost 600 million individuals are infected by human hookworm...
Impetigo - Ozenoxacin Phase lll Trial published
Fri, 20 Jan 2012 08:00:00 PST
The pharmaceutical company Ferrer has received approval to start phase III human trials of ozenoxacin, formulated as a topical treatment for infectious skin conditions. In February 2012, participants are expected to enter the multicenter, randomized, placebo controlled, parallel, double-blinded superiority clinical study, which is scheduled to complete in 2013...
New Drug For Advanced Colorectal Cancer Shows Promise In Trial published
Wed, 18 Jan 2012 03:00:00 PST
An experimental drug for advanced colorectal cancer that available treatments have failed to halt, has shown promise in a clinical trial, says Bayer HealthCare, the company that makes it. The results of the phase III trial show that compared to placebo, regorafenib slowed tumor growth and extended survival...
Medivation And Pfizer Axe their new Alzheimer's drug Dimebon published
Tue, 17 Jan 2012 12:00:00 PST
Pfizer Inc. and Medivation, Inc. announced results from their 'CONCERT' trial today. CONCERT is a Phase 3 trial that evaluated dimebon (latrepirdine), which is used to treat patients with mild-to-moderate Alzheimer's disease. Dimebon is added to ongoing treatment with donepezil HCL tablets...
Preoperative Breast Cancer Treatment May Be Improved By Combining 2 Anti-HER2 Drugs published
Tue, 17 Jan 2012 02:00:00 PST
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent...
Research Misconduct Revealed in UK published
Mon, 16 Jan 2012 10:00:00 PST
A BMJ survey revealed that over one in ten (13%) UK based scientists or doctors have witnessed that colleagues intentionally changed or fabricated data during their research in order to get published, whilst 6% of respondents reported they are aware of possible research misconduct at their institution, that has not been accurately investigated...
In Ovarian Cancer, Faulty Proteins May Prove Significant In Identifying New Treatments published
Mon, 16 Jan 2012 00:00:00 PST
OHSU Knight Cancer Institute study results suggest that more patients than initially thought could potentially be treated with a new class of drugs, PARP inhibitors A constellation of defective proteins suspected in causing a malfunction in the body's ability to repair its own DNA could be the link scientists need to prove a new class of drugs will be effective in treating a...
Missing Data - A Serious Problem In Clinical Research published
Fri, 06 Jan 2012 10:00:00 PST
Missing data is a serious problem in clinical research given that it distorts the scientific record and prevents clinical decisions from being based on the best evidence available. As part of an in-depth BMJ review on the subject, experts on bmj.com warn that patients can be harmed through missing clinical trial data, leading to unnecessary costs to health systems...
Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise In Open-Label Extension Study published
Sun, 01 Jan 2012 01:00:00 PST
Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures (POS), reported positive data in the open-label extension follow up to the company's Phase 2 clinical trial. The data reflects the replication of the effects seen in the double-blind study...
Jennerex Announces First Patient Treated In Phase 2a Clinical Trial Of JX-594 As A Neoadjuvant Therapy In Colorectal Cancer published
Sun, 01 Jan 2012 00:00:00 PST
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver...
Human Trials Initiated For New HIV Vaccine published
Sun, 01 Jan 2012 00:00:00 PST
In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University London, Imperial College, Hull York Medical School (HYMS; University of York) and the Medical Research Council Clinical Trial Unit) and from the Infectious Dis...
"Science" Names HIV Prevention Trial As Breakthrough Of The Year published
Sat, 31 Dec 2011 00:00:00 PST
Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a row that Science selected a trial for which FHI 360 provided scientific leadership and operational support...
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease published
Sat, 31 Dec 2011 00:00:00 PST
Abbott (NYSE: ABT) announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit™ drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking)...
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study published
Sat, 31 Dec 2011 00:00:00 PST
Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel...
Neuralstem's NSI-189 Trial In Major Depressive Disorder Receives FDA Approval To Advance To Phase Ib published
Thu, 29 Dec 2011 01:00:00 PST
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients...
Presentations Highlight Results Of Clinical Data For MLN8237 And VELCADE® In The Treatment Of Lymphoma published
Fri, 23 Dec 2011 01:00:00 PST
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) reported the presentation of results from a phase 2 trial evaluating MLN8237, an investigational inhibitor of Aurora A kinase, in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL)...
Novartis Announces Termination Of ALTITUDE Study With Rasilez®/ Tekturna® In High-Risk Patients With Diabetes And Renal Impairment published
Thu, 22 Dec 2011 01:00:00 PST
Novartis announced that following the seventh interim review of data from the ALTITUDE study with Rasilez®/Tekturna® (aliskiren), a decision to terminate the trial has been taken on the recommendation of the independent Data Monitoring Committee (DMC) overseeing the trial...
Genzyme Reports Top-line Results For TENERE Study Of Oral Teriflunomide In Relapsing Multiple Sclerosis published
Thu, 22 Dec 2011 01:00:00 PST
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif®), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS)...
Potential To Double The Efficacy Of Radiation Therapy published
Tue, 20 Dec 2011 00:00:00 PST
Scientists may have a way to double the efficacy and reduce the side effects of radiation therapy. Georgia Health Sciences University scientists have devised a way to reduce lung cancer cells' ability to repair the lethal double-strand DNA breaks caused by radiation therapy. "Radiation is a great therapy - the problem is the side effects," said Dr. William S...
Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial For Menopausal Hot Flashes published
Mon, 19 Dec 2011 01:00:00 PST
Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced that enrollment has started to the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba™ (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes...
Boehringer Ingelheim Completes Patient Entry For Phase III Trial Programme In Hepatitis C published
Mon, 19 Dec 2011 01:00:00 PST
Boehringer Ingelheim announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV)...
New Data Presented On Phase 3 Trial Of ELIQUIS® (Apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness published
Mon, 19 Dec 2011 01:00:00 PST
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc...
Report On Human Subjects Protection Released By President's Bioethics Commission published
Mon, 19 Dec 2011 00:00:00 PST
The Presidential Commission for the Study of Bioethical Issues has issued its report concerning federally-sponsored research involving human volunteers, concluding that current rules and regulations provide adequate safeguards to mitigate risk...
Bioethics And Better Protection For Human Volunteers published
Fri, 16 Dec 2011 15:00:00 PST
In the 1940s, research funded by the federal government resulted in thousands of Guatemalans being exposed to sexually transmitted diseases without their consent. The Presidential Commission for the Study of Bioethical Issues published its report today that examines safeguards and protections for human volunteers in medical research...
)
|
|
